BIOPROP20 logo

BIOPROP20

Biologically optimised IMRT for Prostate Radiotherapy Hypofractionated radiotherapy with intra-prostatic boosts to tumour nodules in men with intermediate and high risk prostate cancer

BIOPROP20

Biologically optimised IMRT for Prostate Radiotherapy Hypofractionated radiotherapy with intra-prostatic boosts to tumour nodules in men with intermediate and high risk prostate cancer
Funding Clatterbridge Charitable Funds
Portfolio Cancer
Interventions Other
Randomised No
Status Closed
Start Date 31-Jan-2014

Dose-painting radiotherapy for prostate cancer increases the radiation dose only to areas in the prostate containing tumour. Local control probability increases while toxicity is reduced or constant. Moreover, a hypofractionated shorter treatment schedule should improve tumour control. In this pilot study, we test the toxicity of dose-painting radiotherapy used in combination with a 4 week hypofractionated schedule rather than a standard 8 week schedule.